These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 6384752)

  • 1. Tri-Norinyl and Ortho-Novum 7/7/7--two triphasic oral contraceptives.
    Med Lett Drugs Ther; 1984 Oct; 26(672):93-4. PubMed ID: 6384752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the clinical performance of three triphasic oral contraceptives: a multicenter, randomized comparative trial.
    Schilling LH; Bolding OT; Chenault CB; Chong AP; Fleury F; Forrest K; Glick HI; Hasson HM; Heil CG; London RS
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1264-8. PubMed ID: 2655451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three triphasic oral contraceptives now available in U.S.
    Contracept Technol Update; 1985 Jan; 6(1):1-2, 4. PubMed ID: 12279912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A radioimmunoassay for norethindrone (NET): measurement of serum NET concentrations following ingestion of NET-containing oral contraceptive steroids.
    Stanczyk FZ; Brenner PF; Mishell DR; Ortiz A; Gentzschein EK; Goebelsmann U
    Contraception; 1978 Dec; 18(6):615-33. PubMed ID: 750188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The triphasics: insights for effective clinical use.
    Youngkin EQ; Miller LG
    Nurse Pract; 1987 Feb; 12(2):17-8, 23, 26-8. PubMed ID: 3822267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and biological justifications for the use of Triella].
    McGuire JL; Pasquale SA; Castaigne JP
    Rev Fr Gynecol Obstet; 1986 Dec; 81(12):731-6. PubMed ID: 3823727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current status of oral contraceptive clinical development in Japan.
    Kuwabara Y
    Int J Fertil; 1989; 34 Suppl():18-20. PubMed ID: 2576251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative trials of low-dose combined oral contraceptives.
    Edelman DA; Kothenbeutel R; Levinski MJ; Kelly SE
    J Reprod Med; 1983 Mar; 28(3):195-200. PubMed ID: 6854550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial selection of oral contraceptives.
    Reiter SL; Baer LJ
    J Reprod Med; 1990 May; 35(5):547-8. PubMed ID: 2352250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.
    Spellacy WN; Ellingson AB; Tsibris JC
    Fertil Steril; 1989 Jan; 51(1):71-4. PubMed ID: 2642814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial.
    Kaunitz AM
    Contraception; 2000 May; 61(5):295-302. PubMed ID: 10906499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for a triphasic oral contraceptive.
    Pasquale SA
    J Reprod Med; 1984 Jul; 29(7 Suppl):560-7. PubMed ID: 6481710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of Norinyl and Brevicon in three sites in Sri Lanka.
    Basnayake S; de Silva SV; Miller PC; Rogers S
    Contraception; 1983 May; 27(5):453-64. PubMed ID: 6884024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
    Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
    Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial.
    Notelovitz M; Feldman EB; Gillespy M; Gudat J
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1269-80. PubMed ID: 2655452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The probability of side effects with ovral, norinyl 1/50 and norlestrin.
    Berger GS; Edelman DA; Talwar PP
    Contraception; 1979 Nov; 20(5):447-53. PubMed ID: 160860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of Norinyl 1/35 versus Lo-Ovral in Ile-Ife Nigeria.
    Ayangade O; Akinyemi A
    Int J Gynaecol Obstet; 1989 Oct; 30(2):165-70. PubMed ID: 2572488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.